Bionano Genomics forecasts 2026 revenue between $31M and $33M despite flow cell supply constraints impacting growth.
Bionano Genomics (BNGO) announced a Q2 2026 revenue forecast of $31M to $33M, reflecting continued customer adoption of its consumable products. The projection comes despite ongoing supply constraints related to flow cell production, which management cited as a limiting factor for growth.